Leading the way to a new standard of care for gastrointestinal disease
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
Phathom has assembled a leading team of seasoned gastrointestinal and pharmaceutical industry experts with proven experience developing and commercializing highly innovative therapies.
Executive Leadership Team
Tadataka (Tachi) Yamada, M.D., serves as a Venture Partner with Frazier Healthcare Partners and serves as a Director of Agilent Technologies, CSL, and a number of private life sciences companies. As a member of the Frazier Life Sciences team, Dr. Yamada focuses on both creating companies as well as providing strategic guidance to existing portfolio companies. Dr. Yamada was previously Chief Medical Officer and Chief Scientific Officer at Takeda Pharmaceuticals and a member of the company’s Board of Directors. In this role, Dr. Yamada was responsible for all of Takeda’s research and development activities and a budget of nearly $4 billion. Prior to Takeda, Dr. Yamada was President of the Bill & Melinda Gates Foundation Global Health Program in Seattle, where he oversaw over $9 billion in grants for applying technologies to address major health challenges of the developing world. Before joining the Gates Foundation, he was Chairman of Research and Development at GlaxoSmithKline and member of the Board of Directors. Dr. Yamada was the Chief of the Division of Gastroenterology and the Chair of the Department of Internal Medicine at the University of Michigan in Ann Arbor. Dr. Yamada earned his M.D. from New York University School of Medicine and a B.A. in History from Stanford University. He has authored more 150 manuscripts in peer reviewed journals and is the editor of The Textbook of Gastroenterology.
David Socks is a Venture Partner with Frazier Healthcare Partners, where he focuses on company creation. In this capacity, he co-founded Outpost Medicine, Passage Bio, Recida Therapeutics and Scout Bio. Mr. Socks was Chief Executive Officer of Outpost and Scout, and he currently serves as Executive Chairman of Recida and as a Board member of Outpost. Prior to joining Frazier, he co-founded Incline Therapeutics and served as the company’s President and Chief Operating Officer until its sale to The Medicines Company for up to $390 million. Previously, he was a Venture Partner at Windamere Venture Partners, where he co-founded companies including Cadence (acquired by Mallinckrodt for $1.3 billion), Somaxon Pharmaceuticals (acquired by Pernix Therapeutics) and Verus Pharmaceuticals (acquired by AstraZeneca and Shionogi/Sciele). At Cadence, Mr. Socks served as Senior Vice President of corporate development and strategy. He has also worked in private equity and management consulting. Mr. Socks holds a B.S. from Georgetown University and an M.B.A. from Stanford University.
Azmi Nabulsi, M.D., is the former Deputy Chief Medical Officer, Chief Scientific Officer and Head of Global Development at Takeda Pharmaceuticals. In these roles, he led all global research and development, medical, regulatory, operations and data analytics functions. In addition, he led research and development portfolio management strategy and planning, focusing on enhancing the company’s pipeline and productivity. During his 14-year career at Takeda U.S. and Japan, Dr. Nabulsi oversaw global drug development for both early and late stage product candidates, and he was responsible for bringing the majority of Takeda’s 21 new drugs in multiple therapeutic areas and countries to market. He was also responsible for the design and execution of the company’s major research and development transformation, utilizing industry leading approaches to drive innovation. Dr. Nabulsi has led or directed partnerships and alliances in gastroenterology, oncology, immunology, cardiovascular medicine and metabolism. Prior to Takeda, he held leadership positions at Abbott Laboratories, including Head of Immunology and Oncology Ventures. Dr. Nabulsi has an M.D. from Ain-Shams University in Cairo and a M.P.H. from the University of Minnesota.
Aditya Kohli, Ph.D., is a Vice President with Frazier Healthcare Partners, where he focuses on company creation. In addition to Phathom, he co-founded Scout Bio, Passage Bio and Recida Therapeutics and serves on the Board of Scout Bio. Prior to Frazier, Dr. Kohli was a management consultant with McKinsey & Company, where he led engagements advising global biopharmaceutical companies on business development, research and development, and marketing and sales strategy. Dr. Kohli received his Ph.D. from the UC Berkeley and UC San Francisco joint graduate program in bioengineering and holds B.S. and M.Eng. degrees in biological engineering from MIT.
Roger Ulrich, Ph.D., is a Senior Advisor on the Frazier Healthcare Partners Life Sciences team, and brings several decades of both leadership and operational experience within the pharmaceutical industry. Dr. Ulrich was Chief Scientific Officer and a member of the founding Board of Directors of Acerta Pharma through its majority-share acquisition by AstraZeneca. He was previously Co-founder and Chief Development Officer with Calistoga Pharmaceuticals. Calistoga was acquired by Gilead Sciences, and Dr. Ulrich continued with Gilead to help with the Calistoga integration and complete the development of its lead product candidate. Prior to Calistoga, Dr. Ulrich was Senior Scientific Director with Merck Research Laboratories, where he helped guide the Merck integration of Seattle-based Rosetta Inpharmatics. He was also Director of Drug Safety Evaluation at Abbott Laboratories, and was Senior Scientist with both The Upjohn Company and Pharmacia & Upjohn Inc. Prior to his career in the pharmaceutical industry, he held research positions at West Virginia and Michigan State Universities, and at Argonne National Laboratories. He currently serves on the Boards of Acerta Pharma, Remedy Pharmaceuticals, and Aminex, and serves as a scientific advisor to several small companies. Dr. Ulrich received his Ph.D. in cellular and molecular biology from West Virginia University, where he studied the role of protein kinases and cytoskeletal function in cancer. He holds several patents, has authored more than 120 publications and is a Fellow of the Academy of Toxicological Sciences.
Board of Directors
Venture Partner, Frazier Healthcare Ventures
Chief Executive Officer, Phathom Pharmaceuticals
Venture Partner, Frazier Healthcare Ventures
Managing General Partner, Frazier Healthcare Partners